References
1.Chen L, Zhang J, Zhang L, et al. (2012) Meta-analysis of gadoxeticacid disodium (Gd-EOB-DTPA)-enhanced magnetic resonance imaging for the detection of liver metastases. PLoSONE 2012;7:e48681.
2. Matsushima S, Sato Y, YamauraH, et al. Visualization of liver uptake function using the uptake contrast-enhanced ratio in hepatobiliary phase imaging.Magn Reson Imaging. 2014;32:654–659.
doi: 10.1016/j.mri.2014.02.017.
3.KukukGM, Schaefer SG, FimmersR, et al. Hepatobiliary magnetic resonance imaging in patients with liver disease: correlation of liver enhancement with biochemical liver function tests. Eur Radiol. 2014;24:2482–2490.
doi: 10.1007/s00330-014-3291-x.
4. Matsushima S, Sato Y, YamauraH, et al. Preoperative Evaluation of PosthepatectomyLiver Failure Using MRI-Based Liver Function Indices in Child-Pugh Class A. OpenJournal of Radiology. 2016;6:147–156.
5. Murata S, Matsushima S, Sato Y, et al. Predicting chemotherapeutic response for colorectal liver metastases using relative tumor enhancement of gadoxeticacid disodium-enhanced magnetic resonance imaging. AbdomRadiol. doi: 10.1007/s00261-018-1615-z.
6. P. Kickingereder, S. Burth, A. Wick, M. Gotz, O. Eidel, H.P. Schlemmer, K.H. Maier-Hein, W. Wick, M. Bendszus, A. Radbruch, D. Bonekamp, Radiomicprofiling of glioblastoma: identifying an imaging predictor of patient survival with improved performance over established clinical and radiologic risk models, Radiology.2016;280: 880–889.